Analytical study of hydrogen turbopump cycles for advanced nuclear rockets Progress report, Sep. 15, 1964 - Sep. 15, 1965

Hydrogen turbopump cycles for obtaining high engine inlet pressures in advanced nuclear rockets, and data on gaseous nuclear reactors and heavy gas containmen

Parametric Fokker-Planck equation

We derive the Fokker-Planck equation on the parametric space. It is the Wasserstein gradient flow of relative entropy on the statistical manifold. We pull back the PDE to a finite dimensional ODE on parameter space. Some analytical example and numerical examples are presented

Measuring the Effects of Pre-workout Supplementation on Resting Metabolic Rate

Please view abstract in the attached PDF file

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy:potential impact in the landscape of obesity pharmacotherapy

Introduction: Obesity is recognized as a major healthcare challenge. Following years of slow progress in discovery of safe, effective therapies for weight management, recent approval of the glucagon-like peptide 1 receptor (GLP-1R) mimetics, liraglutide and semaglutide, for obesity has generated considerable excitement. It is anticipated these agents will pave the way for application of tirzepatide, a highly effective glucose-dependent insulinotropic polypeptide receptor (GIPR), GLP-1R co-agonist, recently approved for management of type 2 diabetes mellitus. Areas covered: Following promising weight loss in obese individuals in Phase III clinical trials, liraglutide and semaglutide were approved for weight management without diabetes. Tirzepatide has attained Fast Track designation for obesity management by the US Food and Drug Association. This narrative review summarizes experimental, preclinical, and clinical data for these agents and related GLP-1R/GIPR co-agonists, prioritizing clinical research published within the last 10 years where possible. Expert Opinion: GLP-1R mimetics are often discontinued within 24 months meaning long-term application of these agents in obesity is questioned. Combined GIPR/GLP-1R agonism appears to induce fewer side effects, indicating GLP-1R/GIPR co-agonists may be more suitable for enduring obesity management. After years of debate, this GIPR-biased GLP-1R/GIPR co-agonist highlights the therapeutic promise of including GIPR modulation for diabetes and obesity therapy.</p

Indication for π+π−\pi^+ \pi^- scattering in p+pp+p collisions at sNN=\sqrt{s_{_{NN}}} = 200 GeV

A $\rho(770)^0$ mass shift of about -40 MeV/$c^2$ was measured in $p+p$ collisions at $\sqrt{s_{_{NN}}} =$ 200 GeV at RHIC. Previous mass shifts have been observed at CERN-LEBC-EHS and CERN-LEP. We will show that phase space does not account for the $\rho(770)^0$ mass shift measured at RHIC, CERN-LEBC-EHS and CERN-LEP and conclude that there are significant scattering interactions in $p+p$ collisions.Comment: 11 pages and 7 figure

The Elusive Baseline of Marine Disease: Are Diseases in Ocean Ecosystems Increasing?

Disease outbreaks alter the structure and function of marine ecosystems, directly affecting vertebrates (mammals, turtles, fish), invertebrates (corals, crustaceans, echinoderms), and plants (seagrasses). Previous studies suggest a recent increase in marine disease. However, lack of baseline data in most communities prevents a direct test of this hypothesis. We developed a proxy to evaluate a prediction of the increasing disease hypothesis: the proportion of scientific publications reporting disease increased in recent decades. This represents, to our knowledge, the first quantitative use of normalized trends in the literature to investigate an ecological hypothesis. We searched a literature database for reports of parasites and disease (hereafter “disease”) in nine marine taxonomic groups from 1970 to 2001. Reports, normalized for research effort, increased in turtles, corals, mammals, urchins, and molluscs. No significant trends were detected for seagrasses, decapods, or sharks/rays (though disease occurred in these groups). Counter to the prediction, disease reports decreased in fishes. Formulating effective resource management policy requires understanding the basis and timing of marine disease events. Why disease outbreaks increased in some groups but not in others should be a priority for future investigation. The increase in several groups lends urgency to understanding disease dynamics, particularly since few viable options currently exist to mitigate disease in the oceans

Estimating the effects of Bose-Einstein correlations on the W mass measurement at LEP2

The influence of Bose-Einstein correlations on the determination of the mass of the W boson in e+e- -> WW -> 4jet events at LEP2 energies is studied, using a global event weighting method. We find that it is possible to keep the systematic error on the W mass from this source below 20 MeV, if suitable precautions are taken in the experimental analysis.Comment: 12 pages including 3 .eps figures. Paper revised to correct for a software bug which overestimated heavy quark contributio

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?

Recent approval of the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide, for the management of type 2 diabetes mellitus (T2DM) has reinvigorated interest in exploitation of GIP receptor (GIPR) pathways as a means of metabolic disease management. However, debate has long surrounded the use of the GIPR as a therapeutic target and whether agonism or antagonism is of most benefit in management of obesity/diabetes. This controversy appears to be partly resolved by the success of tirzepatide. However, emerging studies indicate that prolonged GIPR agonism may desensitise the GIPR to essentially induce receptor antagonism, with this phenomenon suggested to be more pronounced in the human than rodent setting. Thus, deliberation continues to rage in relation to benefits of GIPR agonism vs. antagonism. That said, as with GIPR agonism, it is clear that the metabolic advantages of sustained GIPR antagonism in obesity and obesity-driven forms of diabetes can be enhanced by concurrent GLP-1 receptor (GLP-1R) activation. This narrative review discusses various approaches of pharmacological GIPR antagonism including small molecule, peptide, monoclonal antibody and peptide-antibody conjugates, indicating stage of development and significance to the field. Taken together, there is little doubt that interesting times lie ahead for GIPR agonism and antagonism, either alone or when combined with GLP-1R agonists, as a therapeutic intervention for the management of obesity and associated metabolic disease